Objective Depression and obesity are two conditions with great impact over global health. This is mainly due to their high prevalence and the morbidity and mortality associated to both. The main aim of the present systematic review is to study the association between obesity and depression and the prognostic implications derived from it.Methods A literature review was performed in the PUBMED database. 18 articles were found (9 cross-sectional studies, 6 longitudinal studies and 3 clinical trials), which were reviewed by critical reading after which a summary of the main conclusions was written.Results These selected articles confirmed that there is indeed a link between depression and obesity, although there are doubts as to the significance of this relationship. Depression is a risk factor for obesity, especially atypical depression and in African-American adolescent males. Obesity is a risk factor for depression, especially in women and for recurrent depressive disorder. The comorbidity between obesity and depression is a risk factor for a bad prognosis illness.Conclusion The relationship between both disorders has been analysed in scientific literature, obtaining significant associations but also contradictory results. The most current data demonstrates that there is a relationship between both entities, although there is no unanimity when it comes to establishing the meaning of this association.
Paliperidone palmitate 6-month formulation (PP6M) offers a promising alternative for maintaining treatment adherence and reducing relapse risk in patients with schizophrenia. However, real-world data on its long-term effectiveness and safety remains limited. To evaluate the effectiveness and safety of PP6M in a real-world setting over 12 months in patients with schizophrenia previously stabilized on monthly (PP1M) or 3-monthly (PP3M) formulations. This was a multicenter, ambispective mirror-image study conducted across 10 Community Mental Health Units in Spain. A total of 158 patients with schizophrenia who switched from PP1M or PP3M to PP6M were followed at baseline, 6 months, and 12 months. Effectiveness was assessed through hospitalization rates, Clinical Global Impression (CGI), and Sheehan Disability Scale (SDS) scores. Safety, adverse effects, and substance use were also analyzed. A significant reduction in hospitalization was observed at 6 and 12 months compared to the prior year. CGI and SDS scores improved significantly over time. Patient retention at 12 months was 83%, resulting in a dropout rate of 17%. The primary reasons for dropout were clinical relapse (40.7%) and patient refusal (29.6%). Adverse events were reported in 38.2% of patients, mostly mild or moderate. A significant reduction in substance use, particularly cocaine, was also noted. Acceptance of PP6M was high, with nursing staff playing a key role in facilitating the transition. PP6M is an effective and well-tolerated option for patients with schizophrenia in real-world clinical practice. It reduces hospitalizations, improves clinical outcomes, and may contribute to decreased substance use.
Introduction: The prevalence of tobacco smoking and high nicotine dependence (ND) in bipolar disorder (BD) is higher than in the general population but lower than in schizophrenia. This study aims to analyse the relationship of smoking behaviours, including age at onset of daily smoking (AODS), with age at onset of BD and course‐of‐illness variables –particularly recurrent suicide attempt– in a community sample of BD patients, also compared in their smoking behaviour variables with a sample of non‐psychiatric adults. Methods: Samples of 108 patients with BD and 290 non‐psychiatric adults were compared in their smoking habit. High ND was defined by a score of ≥ 6 on the Fagerström Test for Nicotine Dependence. Logistic regression analyses were employed to identify factors associated with daily smoking and high ND. Hazard curves were used to compare AODS between patients and controls and, among patients, age of BD onset between smokers and non‐smokers. Within‐subject survival times –AODS and the age at onset of BD symptoms– were compared with a multi‐state illness‐death model. Results: Compared with controls, BD patients showed higher prevalences of current daily smoking (44% vs. 34%) and high ND (25% vs. 9%); and lower smoking cessation rates (23% vs. 38%). Among BD patients, recurrent suicide attempt showed a strong independent association with both daily smoking and high ND. AODS was later in BD patients than the control group. Among patients, illness onset was earlier in smokers and AODS was earlier than illness onset. Conclusion: Addressing tobacco consumption should be an integral component of BD prevention and treatment strategies.